ArticleBiochemistry and biophysics reports2026
Lian-Jia-San-Jie formula suppresses non-small cell lung cancer via FTO-dependent m
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulation of the epitranscriptome is implicated in the aberrant expression of oncogenes during oncogenesis. In this study, we sought to elucidate the therapeutic mechanisms of Lian-Jia-San-Jie-Fang (LJSJF), a traditional Chinese medicinal formula composed of 14 herbs with Methods: We employed a zebrafish xenograft model of lung cancer to quantify cell proliferation and migration. Utilizing bioinformatic tools, we dissected the altered expression patterns of long non-coding RNAs (lncRNAs) within tumor cells following treatment with Lian-Jia-San-Jie-Fang (LJSJF). We further examined the expression levels and prognostic significance of CASC9/CD3EAP in tumor progression using a curated public database of tissue samples. To mechanistically probe the role of m Results: LJSJF exerted dose-dependent anti-proliferative and anti-migratory effects in zebrafish NSCLC xenografts. In-vivo quantitative PCR with human-specific primer pairs was performed on whole zebrafish larvae. Although no off-target amplification from zebrafish genome was detected, these measurements reflect total human-derived transcript abundance in whole-larva lysates rather than per-cell gene expression within tumor cells. The results showed that total transcript levels of human CASC9 and CD3EAP were reduced in a dose-dependent manner in LJSJF-treated xenograft-bearing larvae. RNA-seq screening revealed widespread dysregulation of lncRNAs upon LJSJF intervention, among which oncogenic Conclusion: This study reveals that LJSJF restrains NSCLC malignant phenotypes through epigenetic repression of the FTO-CASC9-CD3EAP axis, providing a potential therapeutic target for NSCLC intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.